v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 239,199 $ 745,461 $ 699,413 $ 1,191,901
General and administrative 3,707,311 1,208,319 11,319,465 2,448,091
Total operating expenses 3,946,510 1,953,780 12,018,878 3,639,992
Loss from operations (3,946,510) (1,953,780) (12,018,878) (3,639,992)
Other income (expense):        
Foreign exchange transaction loss 0 0 (935) 0
Change in fair value of share liability (279,425) (2,903) (109,040) (2,093)
Interest income 3,452 453 4,946 1,907
Total other expense, net (275,973) (2,450) (105,029) (996)
Net loss $ (4,222,483) $ (1,956,230) $ (12,123,907) $ (3,640,988)
Net loss per share, basic and diluted $ (0.14) $ (0.06) $ (0.40) $ (0.13)
Weighted average shares of common stock outstanding, basic and diluted 31,147,749 30,107,127 29,954,321 28,642,533
Other comprehensive loss:        
Net loss $ (4,222,483) $ (1,956,230) $ (12,123,907) $ (3,640,988)
Foreign currency translation (64,644) 150,501 (1,541,170) 275,772
Total comprehensive loss $ (4,287,127) $ (1,805,729) $ (13,665,077) $ (3,365,216)

Source